In accordance with previous PCR analyses of MYD88 in the present cohort [20], we found that primary OA-DLBCL-NOS had a relatively high prevalence of MYD88 pathogenic variants (n = 4, 29%), and that CD79B pathogenic variants were more frequent (n = 3, 21%) than previously detected by PCR [20], possibly due to increased sensitivity by targeted NGS analysis. Here, MYD88 is linked to diffuse large B-cell lymphoma.